Equillium Q2 2024 Earnings Report

Equillium EPS Results

• Actual EPS: $0.01
• Consensus EPS: -$0.15
• Beat/Miss: Beat by +$0.16
• One Year Ago EPS: N/A

Equillium Revenue Results

• Actual Revenue: $13.85 million
• Expected Revenue: $8.15 million
• Beat/Miss: Beat by +$5.70 million
• YoY Revenue Growth: N/A

Equillium Announcement Details

• Quarter: Q2 2024
• Date: 8/8/2024
• Time: N/A

Equillium (NASDAQ:EQ), a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.